Potent and selective inhibitors of Staphylococcus epidermidis tryptophanyl-tRNA synthetase

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 502-509

  Wu, Yang ^a   Yu, Kunqian ^b   Xu, Bin ^a   Chen, Lili ^b   Chen, Xianglong ^c   Mao, Jialing ^a   Danchin, Antoine ^d   Shen, Xu ^b   Qu, Di ^a   Jiang, Hualiang ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d INSTITUT PASTEUR   (France)

Author keywords

Antibacterials; S. epidermidis; Virtual screening; WRS

Indexed keywords

2 [5 [[6 (ETHOXYCARBONYL) 5 (4 FLUOROPHENYL) 3 OXO 7 PHENYL 5H [1,3]THIAZOLO[3,2 A]PYRIMIDIN 2(3H) YLIDENE]METHYL] 2 FURYL]BENZOIC ACID; 3 [[4 [[4 OXO 2 (PHENYLIMINO) 1,3 THIAZOLIDIN 5 YLIDENE]METHYL]PHENOXY]METHYL]BENZOIC ACID; 3 [[[[[2 (4 CHLOROPHENYL) 4 QUINOLINYL]CARBONYL]AMINO]CARBOTHIOYL]AMINO]BENZOIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CHLORAMPHENICOL; TRYPTOPHAN TRANSFER RNA LIGASE; TRYPTOPHAN TRANSFER RNA LIGASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; VERO CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CULTURE MEDIA; ENZYME INHIBITORS; LIGANDS; MICROBIAL SENSITIVITY TESTS; NEPHELOMETRY AND TURBIDIMETRY; RECOMBINANT PROTEINS; STAPHYLOCOCCUS EPIDERMIDIS; SURFACE PLASMON RESONANCE; TRYPTOPHAN-TRNA LIGASE; VERO CELLS;

EID: 34548131228     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm229     Document Type: Article

References (37)

1. Rupp ME, Archer GL. Coagulase-negative staphylococci: Pathogens associated with medical progress. Clin Infect Dis 1994; 19: 231-43; quiz 44-5.
2. Huebner J, Goldmann DA. Coagulase-negative staphylococci: Role as pathogens. Annu Rev Med 1999; 50: 223-36.
3. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: Emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26: 1182-7.
4. Zhang YQ, Ren SX, Li HL et al. Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol 2003; 49: 1577-93.
5. Gill SR, Fouts DE, Archer GL et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol 2005; 187: 2426-38.
6. Kim S, Lee SW, Choi EC et al. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl Microbiol Biotechnol 2003; 61: 278-88.
7. Casewell MW, Hill RL. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985; 15: 523-31.
8. Ochsner UA, Young CL, Stone KC et al. Mode of action and bio-chemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother 2005; 49 4253-62.
9. Cochereau C, Sanchez D, Bourhaoui A et al. Capsaicin, a structural analog of tyrosine, inhibits the aminoacylation of tRNA(Tyr). Toxicol Appl Pharmacol 1996; 141: 133-7.
10. Anderson JW, Fewden L. 1-Amino-2-phenylethane 1-phosphonic acid: A specific competitive inhibitor of phenylalanyl-tRNA synthetase. Chem Biol Interact 1970; 2: 53-5.
11. Balg C, Blais SP, Bernier S et al. Synthesis of β-ketophosphonate analogs of glutamyl and glutaminyl adenylate, and selective inhibition of the corresponding bacterial aminoacyl-tRNA synthetases. Bioorg Med Chem 2007; 15: 295-304.
12. Metitskaya A, Kazakov T, Kommer A et al. Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic Microcin C. J Biol Chem 2006; 281: 18033-42.
13. Hurdle JG, O'Neill AJ, Chopra I. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother 2004; 54: 549-52.
14. Brown MJ, Carter PS, Fenwick AS et al. The antimicrobial natural product chuangxinmycin and some synthetic analogues are potent and selective inhibitors of bacterial tryptophanyl tRNA synthetase. Bioorg Med Chem Lett 2002; 12: 3171-4.
15. Ibba M. Eyeing up trytophanyl-tRNA synthetase. Trends Biochem Sci 2002; 27: 227.
16. Buddha MR, Keery KM, Crane BR. An unusual tryptophanyl tRNA synthetase interacts with nitric oxide synthase in Deinococcus radiodurans. Proc Natl Acad Sci USA 2004; 101: 15881-6.
17. Xu F, Chen X, Xin L et al. Species-specific differences in the operational RNA code for aminoacylation of tRNA(Trp). Nucleic Acids Res 2001; 29: 4125-33.
18. Yu Y, Liu Y, Shen N et al. Crystal structure of human tryptophanyl-tRNA synthetase catalytic fragment: Insights into substrate recognition, tRNA binding, and angiogenesis activity, J Biol Chem 2004; 279: 8378-88.
19. Paley EL, Smelyanski L, Malinovskii V et al. Mapping and molecular characterization of novel monoclonal antibodies to conformational epitopes on NH2 and COOH termini of mammalian tryptophanyl-tRNA synthetase reveal link of the epitopes3 to aggregation and Alzheimer's disease. Mol Immunol 2007; 44:541-57.
20. Otani A, Slike BM, Dorrell MI et al. A fragment of human TrPRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 2002; 99: 178-83.
21. Wemer RG, Thorpe LF, Reuter W et al. Indolmycin inhibit prokaryotic tryptophanyl-tRNA ligase. Eur J Biochem/FEBS 1976; 68: 1-3.
22. Jorgensen WL. The many roles of computation in drug discovery. Science 2004; 303: 1813-8.
23. Qin Z, Zhang J, Xu B et al. Structure-based discovery of inhibitors of the YycG histidine kinase: New chemical leads to combat Staphylococcus epidermidis infections. BMC Microbiol 2006; 6 96.
24. Carter CW, Jr, Crumley KV, Coleman DE et al. Direct phase determination for the molecular envelope of tryptophanyl-tRNA synthetase from Bacillus stearothermophilus by X-ray contrast variation. Acta Crystallogr A 1990; 46: 57-68.
25. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
26. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
27. Bowie JU, Luthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science 1991; 253: 164-70.
28. Ewing TJ, Makino S, Skillman AG et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001; 15: 411-28.
29. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992; 257: 1078-82.
30. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 1996; 9: 1-5.
31. Zheng S, Luo X, Chen G et al. A new rapid and effective chemistry space filter in recognizing a druglike database. J Chem Inf Model 2005; 45: 856-62.
32. Pohlmann J, Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord 2004; 4: 261-72.
33. Kapustina M, Carter CW, Jr. Computational studies of tryptophanyl-tRNA synthetase: Activation of ATP by induced-fit. J Mol Biol 2006; 362: 1159-80.
34. Lee J, Kang MK, Chun MW et al. Methionine analogues as inhibitors of methionyl-tRNA synthetase. Bioorg Med Chem Lett 1998; 8: 3511-4.
35. Schimmel PR, Soll D. Aminoacyl-tRNA synthetases: General features and recognition of transfer RNAs. Annu Rev Biochem 1979; 48: 601-48.
36. Maesaki S, Yamagúchi T, Sasaki K et al. The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa. Jpn Ant/biot 2006; 59: 11-20.
37. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Villanova, PA, USA, 2006.